Health

Heranova Lifesciences Debuts with $13.5 Million Seed and Seed+ Round Funding to Offer Integrated Clinical Solutions to Women's Health

BOSTON and HONG KONG, Dec. 28, 2023 /PRNewswire/ -- Heranova Lifesciences Holding Ltd. ("Heranova") today announced the successful completion of aUSD 13.5 million seed and seed+ financing to develop and offer integrated Women's Health solutions worldwide. This funding will be used to launch a ...

2023-12-28 21:00 1667

Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024

CBL-514 Phase 2 Study Results for local fat reduction demonstrated 85.7% and 76.2% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after receiving CBL-514 treatment(s). NEW TAIPEI CITY, Dec. 26, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Cal...

2023-12-27 11:49 1719

PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site

NANJING, China, Dec. 26, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and ab...

2023-12-27 11:37 1969

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney ...

2023-12-26 17:26 1896

PharmaBlock Obtained ISO 50001 Certification, Advancing Sustainable Development

NANJING, China, Dec. 25, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725. SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced the successful attainment of Energy Management System Certification...

2023-12-26 11:00 1991

Harbin City Pushes for Breakthroughs in Full Revitalization of Northeast China

HARBIN, China, Dec. 25, 2023 /PRNewswire/ -- Harbin, capital of Heilongjiang Province, has strived to build itself into a city of innovation, by sticking to reform and innovation and stimulating endogenous strength to push for breakthroughs in the full revitalization of northeastChina. The Harbi...

2023-12-25 20:42 2110

FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy

NANJING, China, Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. However, the transition from basic research to clinical commercialization presents formidable challenge...

2023-12-25 10:15 2065

APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia

SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-23...

2023-12-24 17:53 2623

GenSci Launches Global Innovation Hub in Shanghai

The Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges SHANGHAI, Dec. 22, 2023 /PRNewswire/ -- Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), h...

2023-12-23 15:41 2921

Yoshitsu Co., Ltd Reports First Six Months of Fiscal Year 2024 Financial Results

TOKYO, Dec. 22, 2023 /PRNewswire/ -- Yoshitsu Co., Ltd ("Yoshitsu" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products inHong Kong, mainland China, Japan, North America...

2023-12-22 19:00 6359

TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma

NANJING, China and GAITHURSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420), ...

2023-12-21 21:45 1396

BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

WUXI, China, Dec. 20, 2023 /PRNewswire/ -- BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) inCh...

2023-12-21 08:26 1592

YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting

GAITHERSBURG, Md., Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-12-21 05:30 1674

/DISREGARD RELEASE: YS Biopharma/

We are advised by YS Biopharma Co., Ltd. (NASDAQ:YS) that journalists and other readers should disregard the news release, "YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting onDecember 28, 2023", issued on December 20, 2023 by YS Biopharma over PR Newswire, as the release contained err...

2023-12-21 05:15 2490

CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors

HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a hospital inChina.  "A single center, single-arm, dose-escalation, exploratory clinical trial to examine t...

2023-12-21 01:00 1658

Genevoyager Unveils Gene Therapy CDMO Facility in Milestone Move

PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ -- Genevoyager (Wuhan) Co., Ltd. (Genevoyager), a leading provider of one-stop CRO/CDMO services for gene therapy products, proudly announces the official opening of its Contract Development and Manufacturing Organization (CDMO) facility. This significant ...

2023-12-20 23:10 1584

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum

ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...

2023-12-20 20:00 1580

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit®  linker-payload pl...

2023-12-20 09:00 1589

Standigm named as a Tech Innovator in Generative AI in Drug Discovery use case

SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discovery and development, today announced that it has been included in a recent Gartner report, entitled,Emerging Tech: Tech Innovators fo...

2023-12-19 22:00 1499

New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA

SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injec...

2023-12-19 20:00 1393
1 ... 43444546474849 ... 273